Visiongain Publishes Antibacterial Drugs Market Report 2020-2030

25 August 2020
Pharma

Visiongain has launched a new pharma report Antibacterial Drugs Market : Forecasts Report of  2020-2030 by Type (Cephalosporins (Rocephin, Sulperazon, Ceftin/Zinnat, Meiact, Flomox, Teflaro, Zeftera, Ceftolozane-tazobactam, Ceftazidime-Avibactam, Others), Penicillins (Generic amoxicillin, Augmentin, Zosyn/Tazocin, Unasyn, Generic Amoxicllin-clavulanic Acid, Amoxil, Others), Fluoroquinolones (Avelox, Cravit, Vigamox, Ciprodex, Cipro/Cirpobay, Geninax, Baxdela, Others), Macrolides (Biaxin/Clarith, Zithromax, Dalacin, Dificid, Solithromycin, Others), by Carbapenems (Invanz, Merrem/Meropen, Primaxin, Doribax, Others), Others (Zyvox, Cubicin, Tygacil, TOBI/TIP, Solodyn, Vibativ, Sirturo, Tedizolid, Oritavancin, Dalbavancin, Nemonoxacin, Surotomycin)), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, E-Commerce), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) and Analysis of Leading Drug Discovery Outsourcing Companies. PLUS, COVID-19 Recovery Scenarios.

This report evaluates the antibacterial drugs market for the period, 2020-2030. The global market is estimated to be worth US$xx million in 2020 and is projected to reach US$xx million in 2030 while growing at a CAGR of xx% over the forecast period from 2020 to 2030.

"The growth of the antibacterial drug market has been relatively stagnant due to generic erosion, lack of new antibacterial drugs entering the market and rising prevalence of treatment-resistant bacteria. Initiatives to regulate the consumption of antibacterial drugs in several national markets, though necessary, have also hampered the growth of this market."
Industry Analyst, Visiongain

Antibacterial drugs form one of the oldest segments of the pharmaceutical industry. More than a hundred new drugs have been launched in this market since the 1940s. However, the strong position of antibiotics is threatened. High use of generic drugs, coupled with a limited pipeline of new therapies, has affected, and will continue to threaten, growth of the antibacterial drugs market. Increasing resistance to current antibiotics is also limiting the treatment choice for healthcare providers.

Although the limited R&D pipeline for new antibacterial drugs, patent expiries and geneticization, will continue to affect the market in the early years of the forecast period 2020 to 2030, opportunities exist. Around seven novel antibacterial drugs will be launched in the next two years, including treatments targeting multidrug-resistant Gram-negative bacterial infections, where high unmet clinical needs exist worldwide.

There are pipeline candidates in this sector that have novel mechanisms of action or improve on existing classes. We discuss the merits of cephalosporin-β-lactases inhibitor combinations, and entirely novel therapeutic monoclonal antibodies targeting S. aureus and P. aeruginosa. This report identifies how industry and market trends affect the drug developers with novel antibiotic therapies, as well as generics manufacturers, and other participants in that industry and market.

Some of the major companies operating in the global antibacterial drugs market are Pfizer Inc., Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, BioVersys AG, Allecra Therapeutics GmbH, Adenium Biotech ApS, Bayer AG, Eli Lilly and Company, Johnson & Johnson Services, Inc., AstraZeneca PLC, Allergan, Melinta Therapeutics, SHIONOGI Co., Ltd., and DAIICHI SANKYO COMPANY, LIMITED among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever